How does obesity affect the endocrine system? A narrative review

Clinical Obesity

Volumn 7, Issue 3, 2017, Pages 136-144

  Poddar, M ^a   Chetty, Y ^b   Chetty, V T ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Endocrine system; obesity; review

Indexed keywords

ESTROGEN; GROWTH HORMONE; INSULIN; PARATHYROID HORMONE; TESTOSTERONE; VITAMIN D;

ENDOCRINE SYSTEM; FEMALE INFERTILITY; HUMAN; HYPERANDROGENISM; HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; OBESITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THYROID GLAND; VITAMIN METABOLISM;

EID: 85047103757     PISSN: 17588103     EISSN: 17588111     Source Type: Journal    
DOI: 10.1111/cob.12184     Document Type: Review

References (59)

1. Revelo XS, Luck H, Winer S, Winer DA. Morphological and inflammatory changes in visceral adipose tissue during obesity. Endocr Pathol 2013; 25: 93–101.
2. Frayn K. Adipose tissue and the insulin resistance syndrome. Proc Nutr Soc 2001; 60: 375–380.
3. Fernandez-Real J-M. Plasma total and glycosylated corticosteroid-binding globulin levels are associated with insulin secretion. J Clin Endocrinol Metab 1999; 84: 3192–3196.
4. Snyder P. Overview of testosterone deficiency in older men. UptoDate. 2016.
5. Menucci M. Endocrine changes in obesity. Endotext 2011: 1–36.
6. Michalakis K, Mintziori G, Kaprara A, Tarlatzis BC, Goulis DG. The complex interaction between obesity, metabolic syndrome and reproductive axis: a narrative review. Metabolism 2013; 62: 457–478.
7. Hautanen A. Synthesis and regulation of sex hormone binding globulin in obesity. Int J Obes Relat Metab Disord 2000; 24: S64–S70.
8. Lima N, Cavaliere H, Knobel M, Halpern A, Medeiros-Neto G. Decreased androgen levels in massively obese men may be associated with impaired function of the gonadostat. Int J Obes Relat Metab Disord 2000; 24: 1433–1437.
9. Bhasin S, Cunningham GR, Hayes FJ et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol 2006; 91: 1995–2010.
10. Bhasin S. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metabol 1997; 82: 407–413.
11. Dimopoulou C, Ceausu I, Depypere H et al. EMAS position statement: testosterone replacement therapy in the aging male. Maturitas 2016; 84: 94–99.
12. Villa J, Pratley RE. Adipose tissue dysfunction in polycystic ovary syndrome. Curr Diab Rep 2011; 11: 179–184.
13. Legro RS, Arslanian SA, Ehrmann DA et al. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol 2013; 98: 4565–4592.
14. Carroll PV, Christ ER, Bengtsson BA et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J Clin Endocrinol Metabol 1998; 83: 382–395.
15. Legro R. Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med 2012; 30: 496–506.
16. Welt CK, Chan JL, Bullen J et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 2004; 351: 987–997.
17. Ehrmann DA, Liljenquist DR, Kasza K et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metabol 2006; 91: 48–53.
18. Rich P. Canadian Medical Associtation. CMA recognized obesity as a disease. URL https://www.cma.ca/En/Pages/cma-recognizes-obesity-as-a-disease.aspx (accessed 10 September 2015).
19. Melmed S. Physiology of growth hormone. UptoDate. 2015
20. Scacchi M. Growth hormone in obesity. Int J Obes (Lond) 1999; 23: 260–271.
21. Llopis MA. Growth hormone-binding protein directly depends on serum leptin levels in adults with different nutritional status. J Clin Endocrinol Metabol 1998; 83: 2006–2011.
22. Nam SY. The growth hormone (GH)-binding protein in obesity with varying glucose tolerance: relationship with body fat distribution, insulin, GH ± insulin-like growth factor (IGF)-I axis and sex hormones. Int J Obes (Lond) 2000; 24: S158–9.
23. Kelijman M, Frohman LA. Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary manipulation in obese and nonobese subjects. J Clin Endocrinol Metabol 1988; 66: 489–494.
24. Pujanek M. Pathomechanisms of the development of obesity in some endocrinopathies – an overview. Endokrynol Pol 2013; 64: 150–155.
25. Nass RM, Gaylinn BD, Rogol AD, Thorner MO. Ghrelin and growth hormone: story in reverse. Proc Natl Acad Sci 2010; 107: 8501–8502.
26. Biller BMK, Sesmilo G, Baum HBA et al. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency 1. J Clin Endocrinol Metabol 2000; 85: 970–976.
27. Arnaldi G, Angeli A, Atkinson AB et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metabol 2003; 88: 5593–5602.
28. Nieman L, Biller B, Findling J et al. The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline. Eur J Endocrinol 2009; 93: 1526–1540.
29. Yanovski JA. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. a new test to distinguish Cushing's syndrome from Pseudo-Cushing's states. JAMA 1993; 269: 2232–2238.
30. Abraham Sb, Rubino D, Sinaii N, Ramsey S, Nieman LK. Cortisol, obesity, and the metabolic syndrome: a cross-sectional study of obese subjects and review of the literature. Obesity 2013; 21: 1.
31. Fleseriu M, Ludlam WH, Teh SH et al. Cushing's syndrome might be underappreciated in patients seeking bariatric surgery: a plea for screening. Surg Obes Relat Dis 2009; 5: 116–119.
32. Findling JW, Raff H. Cushing's syndrome: important issues in diagnosis and management. J Clin Endocrinol Metabol 2006; 91: 3746–3753.
33. Leibowitz G, Tsur A, Chayen SD et al. Pre-clinical Cushing's syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients. Clin Endocrinol (Oxf) 1996; 44: 717–722.
34. Putignano P, Toja P, Dubini A et al. Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for Cushing's syndrome. J Clin Endocrinol Metab 2003; 88: 4153–4157.
35. Rotondi M, Leporati P, La Manna A et al. Raised serum TSH levels in patients with morbid obesity: is it enough to diagnose subclinical hypothyroidism? Eur J Endocrinol 2008; 160: 403–408.
36. Michalaki MA, Vagenakis AG, Leonardou AS et al. Thyroid function in humans with morbid obesity. Thyroid 2006; 16: 73–78.
37. Sousa PAMD, Vaisman M, Carneiro JRI et al. Prevalence of goiter and thyroid nodular disease in patients with class III obesity. Arq Bras Endocrinol Metabol 2013; 57: 120–125.
38. Jeffrey G, Cobin R, Gharib H et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract 2012; 18: 988–1028.
39. Celi FS, Zemskova M, Linderman JD et al. Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine. J Clin Endocrinol Metabol 2011; 96: 3466–3474.
40. Knudsen N, Laurberg P, Rasmussen LB. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metabol 2005; 90: 4019–4024.
41. Janz T. Vitamin D blood levels in Canadians. Statistics Canada Catalogue; no. 82-624-X. 2015.
42. Wright CS, Weinheimer-Haus EM, Fleet JC, Peacock M, Campbell WW. The apparent relation between plasma 25-hydroxyvitamin D and insulin resistance is largely attributable to central adiposity in overweight and obese adults. J Nutr 2015; 145: 2683–2689.
43. Bell NH, Epstein S, Greene A et al. Evidence for alteration of the vitamin D-endocrine system in obese subjects. J Clin Investig 1985; 76: 370–373.
44. Bell NH, Epstein S, Greene A et al. Evidence for alteration of the vitamin D-endocrine system in obese subjects. J Clin Investig 1985; 76: 370–373.
45. Parikh SJ, Edelman M, Uwaifo GI et al. The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metabol 2004; 89: 1196–1199.
46. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000; 72: 690–693.
47. Stokic E, Kupusinac A, Tomic-Naglic D et al. Vitamin D and dysfunctional adipose tissue in obesity. Angiology 2014; 66: 613–618.
48. Cheng S, Massaro JM, Fox CS et al. Adiposity, cardiometabolic risk, and vitamin D status: the Framingham heart study. Diabetes 2009; 59: 242–248.
49. Michalakis K, Goulis DG, Vazaiou A et al. Obesity in the ageing man. Metabolism 2013; 62: 1341–1349.
50. Holick MF, Binkley NC, Bischoff-Ferrari HA et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol 2011; 96: 1911–1930.
51. Kalupahana NS, Moustaid-Moussa N. The renin-angiotensin system: a link between obesity, inflammation and insulin resistance. Obes Rev 2011; 13: 136–149.
52. Bentley-Lewis R, Adler GK, Perlstein T et al. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metabol 2007; 92: 4472–4475.
53. Srinivasa S, Fitch KV, Wong K et al. RAAS activation is associated with visceral adiposity and insulin resistance among HIV-infected patients. J Clin Endocrinol Metabol 2015; 100: 2873–2882.
54. Huby AC, Antonova G, Groenendyk J et al. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis: clinical perspective. Circulation 2015; 132: 2134–2145.
55. Garg R, Hurwitz S, Williams GH, Hopkins PN, Adler GK. Aldosterone production and insulin resistance in healthy adults. J Clin Endocrinol Metabol 2010; 95: 1986–1990.
56. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 2004; 43: 518–524.
57. Hiramatsu K, Yamada T, Ichikawa K, Izumiyama T, Nagata H. Changes in endocrine activities relative to obesity in patients with essential hypertension. J Am Geriatr Soc 1981; 29: 25–30.
58. Nishizaka M. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925–930.
59. Rocha R, Stier CT, Kifor I et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy 1. Endocrinology 2000; 141: 3871–3878.